 Collaborations and PartnershipsTo bring the most benefit of our technology platform to physicians and their patients, EyeGate Pharma will look to partner third-party compounds that are in development or are in clinical trials in the field of ophthalmology. The EyeGate ocular iontophoretic technology is applicable to a broad range of active compounds and is ideal for delivering efficacious dosages in a non-invasive and safe manner. The EyeGate® II Delivery System delivers an increased intraocular drug concentration which is important for treating diseases such as uveitis, AMD (choroidal/retinal neovascularization), glaucoma (neuroprotectants) and diabetic retinopathy. The EyeGate® II Delivery System can successfully deliver an increased drug concentration in the ocular coats (Conjunctiva, Sclera, Choroid and Retina) which is useful for treating diseases including dry eye syndrome, herpetic keratitis, uveitis and CNV. The platform technology has also demonstrated an increase in cellular uptake. The ability to deliver intracellularly has benefits for treatments using siRNA's and neuroprotecants, to name a few. Core competencies include formulating the ideal medium for delivery of the drug via the EyeGate device, expertise in ocular drug delivery and a comprehensive knowledge of ocular iontophoresis. If your organization is interested in learning more about EyeGate Pharma and potential product partnering opportunities, please contact us today. |
|
 |
